GEMIN X PHARMACEUTICALS
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
GEMIN X PHARMACEUTICALS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.geminx.com
Total Employee:
1+
Status:
Active
Contact:
(514)281-8989
Email Addresses:
[email protected]
Total Funding:
71.26 M USD
Technology used in webpage:
SPF Nginx DOSarrest Uniregistry
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Current Employees Featured
Founder
Investors List
Sanderling Ventures
Sanderling Ventures investment in Series E - Gemin X Pharmaceuticals
Caxton Advantage Life Sciences Fund
Caxton Advantage Life Sciences Fund investment in Series E - Gemin X Pharmaceuticals
Sanderling Ventures
Sanderling Ventures investment in Series D - Gemin X Pharmaceuticals
Caxton Advantage Life Sciences Fund
Caxton Advantage Life Sciences Fund investment in Series D - Gemin X Pharmaceuticals
SB Life Science
SB Life Science investment in Series C - Gemin X Pharmaceuticals
VantagePoint Capital Partners
VantagePoint Capital Partners investment in Series C - Gemin X Pharmaceuticals
Sanderling Ventures
Sanderling Ventures investment in Series C - Gemin X Pharmaceuticals
Canadian Medical Discoveries Fund
Canadian Medical Discoveries Fund investment in Series C - Gemin X Pharmaceuticals
Merlin Biomed
Merlin Biomed investment in Series C - Gemin X Pharmaceuticals
HBM Partners
HBM Partners investment in Series C - Gemin X Pharmaceuticals
Official Site Inspections
http://www.geminx.com
- Host name: 104.247.81.53
- IP address: 104.247.81.53
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
